Latest Earnings Results: Q3 '26
Estimated EPS
-$0.27
Reported EPS
-$0.15
Surprise
+43.82%
Estimated Rev
$147.96M
Reported Rev
$150.67M
Surprise
+1.83%
• Reported GAAP EPS of -$0.15 up 31.82% YoY • Reported revenue of $150.67M up 1.12% YoY • 10x Genomics expects full year 2026 revenue of $625M to $635M, with 4% to 6% growth over full year 2025 excluding non-recurring license and royalty revenue related to patent litigation settlements.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$0.22 | -- | -- | N/A |
Q3 '26 | -$0.27 | -$0.15 | 43.82% | BEAT |
Q2 '26 | -$0.24 | -$0.14 | 42.41% | BEAT |
Q1 '26 | -$0.28 | -$0.10 | 63.65% | BEAT |
Q4 '25 | -$0.20 | -$0.13 | 35.89% | BEAT |